Group 1 - The core transaction on November 14 involved a block trade of 30,900 shares of Mindray Medical, with a transaction value of 5.4625 million yuan, at a price of 176.78 yuan, representing a discount of 14.89% compared to the closing price of the day [2][3] - Over the past three months, Mindray Medical has recorded a total of 13 block trades, amounting to a cumulative transaction value of 232 million yuan [2] - The closing price of Mindray Medical on the day of the transaction was 207.70 yuan, reflecting a slight decline of 0.24%, with a daily turnover rate of 0.43% and a total trading volume of 1.08 billion yuan [2] Group 2 - The latest margin financing balance for Mindray Medical stands at 4.114 billion yuan, having decreased by 118 million yuan over the past five days, which is a decline of 2.78% [3] - Mindray Medical was established on January 25, 1999, with a registered capital of 12.124 billion yuan [3]

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2025-11-14 | 300760 | 迈瑞医疗 | 176.78 | 3.09 | | 546.25 招商证券股份有限 | 申万宏源证券有限 | | | | | | | | 公司深圳蛇口工业 三路证券营业部 | 公司安徽分公司 | 11月14日，迈瑞医疗大宗交易成交3.09万股，成交额546.25万元，占当日总成交额的0.5%，成交价 176.78元，较市场收盘价207.7元折价14.89%。 ...

丨证券研究报告丨 [Table_scodeMsg1] 公司研究丨点评报告丨迈瑞医疗（300760.SZ） [Table_Title] 业绩符合预期，收入拐点已现 报告要点 [Table_Summary] 业绩符合预期，收入迎来增长拐点。公司 2025 年第三季度营业收入 90.91 亿元，同比增长 1.53%；经营性现金流 33.51 亿元，同比增长 30.02%，主要是由于国内市场 2025 年上半年设 备招标活动恢复，营业收入同比降幅明显收窄，四季度业绩有望延续环比持续改善的趋势，国 内业务 2026 年有望回归正增长。2025 年第三季度海外市场提速，收入占比超过 50%。2025 年第三季度公司海外收入增长 11.9%，回到双位数增长水平，其中欧洲市场增长 29%。 分析师及联系人 [Table_Author] 彭英骐 徐晓欣 SAC：S0490524030005 SAC：S0490522120001 SFC：BUZ392 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 [Table_scodeMsg2] 迈瑞医疗（300760.SZ） cjzqdt11 ...

Core Viewpoint - The ChiNext Index has experienced a decline of 1.78% as of November 14, 2025, with mixed performance among constituent stocks, indicating volatility in the market driven by momentum reversal effects and core asset accumulation [1] Group 1: Market Performance - The leading stocks include QianDao Intelligent, which rose by 5.76%, and YiHuaLu, which increased by 3.99%, while JiangBoLong fell by 9.26% [1] - The ChiNext ETF (159908) decreased by 1.62%, with the latest price at 2.92 yuan, but has seen a cumulative increase of 3.99% over the past month [1] - The trading volume for the ChiNext ETF was 14.02 million yuan, with a turnover rate of 1.13% [1] Group 2: Valuation and Economic Signals - Current market valuation levels are near historical averages, with clearer signals of macroeconomic recovery emerging [1] - The analysis suggests that the ChiNext Index has a relatively certain horizontal comparison in terms of allocation space, particularly in the new energy sector, which is a focus area for reversing internal competition [1] - Prices for upstream silicon materials have stabilized, but downstream demand may face challenges related to commercial inventory, leading to market uncertainty [1] Group 3: ETF and Index Composition - The latest scale of the ChiNext ETF is 1.248 billion yuan, closely tracking the ChiNext Index, which consists of 100 stocks with high market capitalization and liquidity [2] - As of October 31, 2025, the top ten weighted stocks in the ChiNext Index account for 58.2% of the index, including companies like Ningde Times and Zhongji Xuchuang [2]

Core Insights - The healthcare innovation sector is showing positive momentum, with the China Securities Medicine and Medical Device Innovation Index (931484) rising by 0.31% as of November 14, 2025, and several key stocks, including Sanofi and Ganli Pharmaceutical, experiencing significant gains [1] Group 1: Market Performance - The China Securities Medicine and Medical Device Innovation Index has seen a 0.31% increase, with notable stock performances: Sanofi up 4.64%, Ganli Pharmaceutical up 3.28%, and Jiutian Pharmaceutical up 1.83% [1] - The Medical Innovation ETF (516820) has also risen by 0.26%, marking its third consecutive increase [1] Group 2: Clinical Developments - AstraZeneca announced successful Phase III clinical trials for Baxdrostat, which significantly reduced 24-hour average systolic blood pressure in patients with resistant hypertension over 12 weeks, indicating a new treatment pathway for hypertension [1] Group 3: Industry Trends - According to Dongfang Caifu Securities, the pharmaceutical industry showed improvement in Q3 2025, with the medical device sector experiencing a turning point, achieving positive year-on-year revenue growth and a notable narrowing of net profit declines [1] - The CXO sector performed exceptionally well in the first three quarters of 2025, with medical R&D outsourcing revenue increasing by 12.2% and net profit rising by 56.8%, particularly in ADC CDMO and peptide CDMO fields [2] - The index reflects the performance of 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors, with the top ten stocks accounting for 64.12% of the index [2]

格隆汇11月13日｜中信建投证券研报指出，迈瑞医疗Q3业绩符合预期，收入增速如期转正，利润端受 毛利率下降、费用率提升影响有所承压。Q4收入增速预计较Q3进一步提升，Q4利润预计在低基数下实 现增长，但考虑到前三季度利润下滑幅度较大，且今年整体利润率承压，预计全年公司归母净利润将有 双位数下滑。展望明年，预计公司将走出行业外部压力带来的影响，回归收入、利润稳健增长轨道。中 长期来看，公司重视研发创新和国际化，拥有高效的研发体系和优秀的渠道管理能力，外延并购有望进 一步拓展布局，加上公司国际化进度持续推进，该行看好公司未来加快迈向全球医疗器械Top10 公司的 步伐。维持"买入"评级。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector, indicating a positive outlook for investment opportunities in this industry [4]. Core Insights - The pharmaceutical sector is experiencing performance divergence, with the medical device segment showing signs of a turning point [1]. - For the first three quarters of 2025, the total revenue of 461 A-share pharmaceutical companies was CNY 17,876.4 billion, a year-on-year decrease of 2%, while net profit attributable to shareholders was CNY 1,435.7 billion, down 6.43% year-on-year [10][29]. - In Q3 2025, the industry showed signs of improvement, with total revenue reaching CNY 5,936.9 billion, a year-on-year increase of 0.51%, and net profit of CNY 419.4 billion, down only 0.95% year-on-year [33]. Summary by Sections 1. Market Review - The pharmaceutical and biotechnology index increased by 21.1% year-to-date, outperforming the CSI 300 index by 3.17 percentage points, with the medical services sub-sector showing the highest growth at 40.25% [17]. 2. Industry Performance - The medical commercial and medical service sectors are the only segments showing positive revenue growth in the first three quarters of 2025, with revenues of CNY 7,723.1 billion and CNY 1,374.9 billion, respectively [29]. - The chemical preparation and medical service sectors demonstrated significant profit growth in Q3, with net profits increasing by 10.43% and 25.80%, respectively [33]. 2.1 Raw Materials and Auxiliary Drugs - The raw materials sector reported total revenue of CNY 670.65 billion, down 7.56% year-on-year, with net profit of CNY 61.01 billion, down 11.18% year-on-year [35]. - The report suggests focusing on high-quality raw material companies such as Shanhe Pharmaceutical and Weier Pharmaceutical [42]. 2.2 Chemical Preparations & Innovative Drugs - The chemical preparations sector achieved total revenue of CNY 3,050.25 billion, down 3.79% year-on-year, with net profit of CNY 320.73 billion, down 15.09% year-on-year [43]. - The report highlights the significant growth of innovative drugs, with 43 new drugs approved in the first half of 2025, a 59% increase year-on-year [47]. 2.3 Traditional Chinese Medicine - The traditional Chinese medicine sector reported total revenue of CNY 2,512.22 billion, down 3.84% year-on-year, with net profit of CNY 292.63 billion, down 1.16% year-on-year [49]. - The sector is transitioning towards quality-oriented development, with a focus on improving the quality of raw materials [57]. 2.4 Biological Products - The biological products sector reported total revenue of CNY 802.59 billion, down 15.34% year-on-year, with net profit of CNY 123.48 billion, down 28.73% year-on-year [58]. - The report suggests monitoring companies with strong internationalization efforts, such as Kangtai Biological [62]. 2.5 Medical Commerce - The medical commerce sector achieved total revenue of CNY 7,723.15 billion, up 0.56% year-on-year, with net profit of CNY 160.9 billion, up 4.94% year-on-year [63]. - The report emphasizes the importance of diversified development in pharmacies, supported by national policies promoting health consumption [68].

11月10日，国产医疗器械行业龙头迈瑞医疗（300760）递交港股上市申请书。 2025年前三季度，公司的研发投入达26.86亿元，超过10%的营收占比。据统计，自A股上市以来，公司 累计的研发投入超过200亿元，研发人员占比常年保持在30%左右，远高于行业平均水平。 而在外延并购方面，公司登陆A股以来并购动作不断。2021年，迈瑞医疗收购芬兰HyTest，解决耗材上 游核心原材料"卡脖子"的问题，提升IVD耗材质量；2023年，收购德国DiaSys，继续深化IVD相关业务 布局，完善海外供应链、丰富产品类别；2024年收购科创板上市医疗企业惠泰医疗，进入电生理与心血 管器械及相关耗材领域，为公司未来发展带来了新的增长点。 根据招股书披露，本次港股发行采用香港公开发售与国际配售相结合的方式，具体发行规模将结合市场 情况综合确定，而公司的募资用途主要有：加码全球研发投入，加强产品及数智化解决方案的创新；探 索潜在的全球并购和合作，加速核心业务增长，拓展升级流水型业务；进一步提升全球销售网络及供应 链能力等。 多年来，迈瑞医疗依托"自主研发"与"外延并购"不断强化核心竞争力。当前，公司现已跻身全球Top30 医疗 ...

Core Viewpoint - The article highlights the performance of the Chuangye 50 ETF (159682), which has shown a significant increase in value and notable movements in its constituent stocks as of November 13. Group 1: ETF Performance - The Chuangye 50 ETF (159682) rose by 2.44%, reaching a price of 1.472 yuan, with a trading volume of 203 million yuan [1] - Since its inception on December 23, 2022, the fund has achieved a return of 43.51%, with a monthly return of 0.91% [1] Group 2: Constituent Stocks Performance - Notable stock movements include: - Ningde Times increased by 8.18% - Zhongji Xuchuang decreased by 2.19% - Dongfang Caifu rose by 0.57% - Xinyi Sheng fell by 1.85% - Sunshine Power increased by 2.72% - Shenghong Technology remained unchanged - Huichuan Technology rose by 1.44% - Mindray Medical increased by 0.13% - Yiwei Lithium Energy surged by 10.71% - Tonghuashun rose by 1.73% [1]

Group 1: Lithium Battery Industry - The lithium battery industry has shown significant performance recovery in the first three quarters of 2025, with total revenue reaching 636.19 billion yuan, a year-on-year increase of 16.12% [1] - The net profit attributable to shareholders reached 62.62 billion yuan, marking a year-on-year growth of 40.37% [1] - The battery and cathode material segments performed particularly well, with Q3 net profit for the battery segment increasing by 53.61% year-on-year and 26.62% quarter-on-quarter [1] - Cathode materials transitioned from loss to profit, with substantial recovery in both year-on-year and quarter-on-quarter net profit in Q3 [1] - The stabilization of lithium carbonate prices and sustained terminal demand are expected to continue the performance recovery trend for midstream material manufacturers [1] Group 2: Communication Industry - The communication industry is experiencing strong growth driven by AI, with the Shenwan Communication Index showing a year-to-date increase of 63.37% as of November 7, 2025 [1] - Major North American cloud service providers, including Microsoft, Google, Meta, and Amazon, reported a combined capital expenditure growth of over 60% year-on-year in the first three quarters of 2025 [1] - The demand for high-speed optical modules is expected to increase, with NVIDIA's next-generation Vera Rubin architecture increasing the demand ratio for 1.6T optical modules from 1:2.5 to 1:5 [1] - The AI industry is entering a phase of explosive growth, with mobile phones and PCs undergoing comprehensive AI integration, propelling the industry into a high-growth trajectory [1] Group 3: ChiNext ETF Performance - As of November 13, 2025, the ChiNext Index (399006) rose by 1.88%, with constituent stocks such as Xinzhou Bang (300037) and Tianhua New Energy (300390) seeing increases of 18.38% and 12.95%, respectively [2] - The ChiNext ETF Ping An (159964) has seen a nearly 30% increase over the past three months, with a current price of 2.07 yuan [2] - The ETF has a one-year average daily trading volume of 8.12 million yuan, indicating strong liquidity [2] Group 4: ChiNext ETF Risk and Fee Structure - The ChiNext ETF Ping An has a management fee rate of 0.15% and a custody fee rate of 0.05%, which are among the lowest in comparable funds [3] - The ETF closely tracks the ChiNext Index, which consists of 100 stocks with high market capitalization and liquidity, reflecting the performance of the ChiNext market [3] - As of October 31, 2025, the top ten weighted stocks in the ChiNext Index accounted for 58.2% of the index [4]